Horizon 2020 - SME-instrument: Neurescue

Horizon 2020 - SME-instrument: Neurescue

Neurescue, a medical device manufacturer based in Denmark, is developing cardiovascular devices to help emergency patients. Their first product, the NEURESCUE device, is the first computer-aided aortic occlusion catheter. This procedure redirects blood flow to the central circulation. Their future goal is to enable the clinical utility of further intelligent procedures.

Current procedures for the treatment of cardiac arrest and critical hemorrhage involves expensive and heavy equipment led by specialized physicians. This entails significant risk for the patient through the requirement of limited personel in a time-consuming process with immobile equipment. This need is being addressed by Neurescue that have developed a device and related sensor technology that enables a safe and accurate computer-aided aortic occlusion. 

The NEURESCUE device is a portable medical device that has the potential to to deliver the necessary vital blood perfusion pressure and that is able to work in synergy with standard procedures, significantly improving their probability of success both inside and outside hospital premises. 

Innovayt A/S has helped Neurescue secure a grant through EU’s SME Instrument Phase II for further market maturation of the NEURESCUE device.

Neurescue Director of Business Development, Bjørn Glavind says: “In terms of pursuing soft funding for Neurescue, working with Innovayt was the best decision we made. Having never gone through similar processes, the Innovayt team were vital support in all steps of the applications processes, from high-level elements such as funding selection and strategy, to the writing process and the nitty gritty submission elements. We warmly recommend Innovayt as a strategic soft-funding partner.”

The challenge

Worldwide, cardiovascular diseases are amongst the leading causes of death and disability. Nearly half of mortalities are due to sudden cardiac arrest incidents. Such incidents are recognized as a major public health problem leading to severe brain tissue damage among patients and survival rates below 10%.

The result

safeREBOATM has the capability to increase survival rates from cardiac arrest and to extend the critical time window necessary (from 15-30 min up to 60 min) to bring a cardiac arrest patient back to normal heart function. The device therefore holds the potential to significantly improve emergency aid and contribute to overall public health.


Tell us about your project

We are always willing to give you a quick assessment of support options for your project. Do you have a relevant idea, please contact us to discuss your options:

Describe your project here